Lyell Immunopharma Inc.
LYEL | NASDAQ
$11.08
+$0.15 (+1.37%)
Sep 22, 2026, 10:54 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 36K | 61K | 130K | 84.68M | 10.65M | 7.76M |
Cost of Revenue | 11.54M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -11.5M | 61K | 130K | 84.68M | 10.65M | 7.76M |
Operating Income | -203.77M | -358.76M | -247.01M | -187.06M | -214.78M | -211.94M |
Interest Income | 13.08M | 24.07M | 23.45M | 7.05M | 1.17M | 5.94M |
Pretax Income | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M | -204.47M |
Net Income | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M | -204.47M |
Selling & General & Admin | 45.14M | 52.04M | 66.98M | 117.31M | 89.06M | 46.88M |
Research & Development | 158.68M | 171.6M | 182.95M | 159.19M | 138.69M | 182.24M |
Other Expenses | -11.54M | 135.17M | -2.79M | -4.75M | -2.32M | -9.43M |
Operating Expenses | 192.27M | 358.82M | 247.14M | 271.74M | 225.43M | 219.69M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 203.81M | 358.82M | 247.14M | 271.74M | 225.43M | 219.69M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M | 12.33M |
Shares Outstanding (Diluted) | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M | 12.33M |
EPS (Basic) | -16.06 | -1.31 | -0.93 | -0.74 | -1.03 | -0.84 |
EPS (Diluted) | -16.06 | -1.31 | -0.93 | -0.74 | -1.03 | -0.84 |
EBITDA | -262.91M | -200.64M | -214.38M | -165.1M | -236.6M | -215.43M |
EBIT | -274.45M | -220.27M | -234.63M | -183.12M | -250.22M | -219.72M |
Depreciation & Amortization | 11.54M | 19.63M | 20.25M | 18.02M | 13.62M | 4.29M |
Add to Watchlist
Select watchlists to add or remove LYEL